Positron Emission Tomography (PET) Study
- Registration Number
- NCT00886067
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
- Physically healthy volunteers
- Body weight between 50 to 100 kg and body mass index (BMI) between 19 and 30 kg/m2
Exclusion Criteria
- History of any clinically significant disease or disorder
- History of severe allergy/hypersensitivity reactions
- Participation in a PET examination as part of a scientific study during the past twelve months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 2-[18F]-F-A85380 2-[18F]-F-A85380 Single microdose AZD1446 AZD1446 Single oral administration
- Primary Outcome Measures
Name Time Method Determine whether and to what extent AZD1446 can displace radioligand 2-[18F]-F-A85380 from binding to α4β2 neuronal nicotinic receptors (NNRs) and to describe the relationship between plasma concentrations of AZD1446 and its occupancy at α4β2 NNRs. One PET assessment on baseline day and one PET assessment at the drug treatment day Plasma concentration (Cmax, tmax, AUC) During time period of the PET assessment
- Secondary Outcome Measures
Name Time Method Safety and tolerability (AEs, vital signs, lab) During the whole study
Trial Locations
- Locations (1)
Research Site
🇸🇪Stockholm, Sweden